Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$3.29
+0.03 (+0.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $659.1M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.9B
P/E
329.0x
↑EV/EBITDA
14.8x
↑ROE
0.2%
↓Gross Margin
52.8%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-9.0%
FCF CAGR
—
FCF margin
11.4%
FCF / Net income
30.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.78B · net income $21.5M · FCF $659.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.78B | $5.78B | $6.11B | $6.65B | $7.67B |
| Net Income | $21.5M | $21.5M | $506.6M | $624.2M | $687.3M |
| EBITDA | $445.5M | $445.5M | $1.01B | $1.09B | $1.17B |
| EPS | 0.01 | 0.01 | 0.17 | 0.21 | — |
| Gross Margin | 52.8% | 52.8% | 54.1% | 57.7% | 57.9% |
| Operating Margin | 4.5% | 4.5% | 10.5% | 12.7% | 14.8% |
| Net Margin | 0.4% | 0.4% | 8.3% | 9.4% | 9.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.18 | 0.25 | 0.25 |
| Current Ratio | 4.70 | 4.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $659.1M | $659.1M | $1.18B | $-24.9M | $-285.9M |
| Returns | |||||
| ROE | 0.2% | 0.2% | 5.8% | 7.5% | 8.8% |
| Valuation | |||||
| P/E | 329.00 | 329.00 | 24.59 | 27.86 | — |
| EV/EBITDA | 14.84 | 14.84 | 12.24 | 16.72 | 21.25 |
| P/B | 0.82 | 0.82 | 1.43 | 2.10 | 3.10 |
| Growth & Yield | |||||
| Revenue Growth | -5.3% | -5.3% | -8.1% | -13.3% | — |
| EPS Growth | -94.1% | -94.1% | -19.0% | — | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
207.9%
EPS terminal req.
$0.29
Spread vs growth
-302.0%
5Y implied EPS CAGR
104.0%
EPS terminal req.
$0.35
Spread vs growth
-198.1%
10Y implied EPS CAGR
49.8%
EPS terminal req.
$0.57
Spread vs growth
-143.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.7%
Start / end P/E
20.9x → 329.0x
EPS bridge
0.17 → 0.01
Residual
-1384.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.